AI-Powered 'Depression Thermometer' Aims to Halve Relapse Rates in TRD Patients
Hope Therapeutics has teamed up with Emobot Health to bring AI-driven mental health monitoring into its psychiatry clinics. The partnership will roll out Emobot's 'Depression Thermometer' across Hope's network The collaboration focuses on a major gap in TRD treatment: nearly half of patients relapse within six to twelve months, often without warning between appointments. Emobot's platform works quietly in the background, using a smartphone to analyse facial expressions, speech patterns, and daily activity. This replaces traditional questionnaires with passive, continuous monitoring.
Patients will receive real-time mood and activity updates through the Emobot app. If early signs of relapse appear, the system sends alerts and helps users book follow-up sessions immediately. Clinicians gain access to an objective data stream, validated by studies showing strong alignment with standard scales like MADRS (r=0.89) and PHQ-9 (r=0.83). Hope Therapeutics expects the integration to double success rates by catching relapses early. Timely interventions—such as maintenance ketamine therapy or TMS—can then be deployed before symptoms worsen. Jonathan Javitt, CEO of Hope Therapeutics, described Emobot's AI as a breakthrough, offering a '360-degree view' of a patient's emotional state. The goal is to shift care from reactive to proactive, with patients playing an active role in their recovery. Preliminary data supports the tool's accuracy, showing it tracks mood changes as effectively as clinician-administered assessments. By removing the burden of self-reporting, the system aims to keep engagement high while reducing missed warning signs.
The partnership will give patients and clinicians a new way to monitor mental health between visits. With automated alerts and validated data, the system targets earlier interventions to prevent relapse. If successful, the approach could set a new benchmark for long-term depression care.
